Alzinova AB (STU:78D) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Alzinova AB Days Payable?

Alzinova AB's average Accounts Payable for the three months ended in Dec. 2024 was €0.29 Mil. Alzinova AB's Cost of Goods Sold for the three months ended in Dec. 2024 was €-0.46 Mil.

The historical rank and industry rank for Alzinova AB's Days Payable or its related term are showing as below:

STU:78D's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 124.08
* Ranked among companies with meaningful Days Payable only.

Alzinova AB's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Alzinova AB Days Payable Historical Data

The historical data trend for Alzinova AB's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzinova AB Days Payable Chart

Alzinova AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

Alzinova AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Alzinova AB's Days Payable

For the Biotechnology subindustry, Alzinova AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzinova AB's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzinova AB's Days Payable distribution charts can be found below:

* The bar in red indicates where Alzinova AB's Days Payable falls into.

Save Embed

;

Save Embed

;

Alzinova AB Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Alzinova AB's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (0.223	+	0.232)	/	2 )	/	-1.458	*	365
=	0.2275					/	-1.458	*	365
=	N/A

Alzinova AB's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (0.345	+	0.232)	/	2 )	/	-0.461	*	365 / 4
=	0.2885					/	-0.461	*	365 / 4
=	N/A

Alzinova AB Days Payable Related Terms

Thank you for viewing the detailed overview of Alzinova AB's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Alzinova AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzinova AB (STU:78D) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

ALZ:Sweden

Address

Pepparedsleden 1, Molndal, SWE, SE-431 83

Website

https://www.alzinova.com

Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is engaged in the development of a specific oligomer-directed vaccine (ALZ-101), and ALZ-201 which is a monoclonal antibody that is specific for the toxic AB oligomers. The products of the company are in the clinical and preclinical stages of development as a therapeutic vaccine for the treatment of Alzheimer's.

Alzinova AB Headlines

No Headlines